NCT03786224

Brief Summary

This study is a critically important first-of-its-kind investigation of the potential research utility of using contingency management to examine long-term changes in cannabis use with six months of abstinence. These pilot data will inform a later trial which will focus on testing the longitudinal relationships between adolescent cognition and cannabis use, questions of high and growing public health significance given adolescents' increased access to cannabis with legalization.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
6

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 17, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 24, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 6, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 6, 2019

Completed
4.7 years until next milestone

Results Posted

Study results publicly available

August 2, 2024

Completed
Last Updated

August 2, 2024

Status Verified

February 1, 2024

Enrollment Period

5 months

First QC Date

December 17, 2018

Results QC Date

February 21, 2024

Last Update Submit

February 21, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Continuous Abstinence Via Progressive Declines in Urine THCCOOH

    Cannabis abstinence will be indexed by progressively decreasing quantitative levels (ng/mL) of 11-nor-delta-9-THC-9-carboxylic acid (THCCOOH), the primary cannabis metabolite, in urine. Residual cannabinoid excretion will be differentiated from new cannabis exposure using a statistical model developed by Schwilke and colleagues (2011). This model was empirically derived from urine CN-THCCOOH concentration ratios of consecutively collected specimen pairs (current specimen/prior specimen). This model takes into account the time between collection of specimens, which enhances the accuracy of prediction of new cannabis use. This formula yields an expected CN-THCCOOH ratio associated with specimen pairs during abstinence, and observed ratios that exceed this expected value are interpreted as new cannabis use.

    Six months

Study Arms (1)

Abstinent

EXPERIMENTAL
Behavioral: Contingency Management

Interventions

Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.

Abstinent

Eligibility Criteria

Age13 Years - 19 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Male and female adolescents actively enrolled in a middle or high school in the Boston area who are between the ages of 13 and 19 (inclusive);
  • Average use of cannabis at least 3 times per week during the 3 months prior to study enrollment;
  • Cannabis use reported within 7 days of study enrollment;
  • No immediate plan to discontinue cannabis use;
  • Have a parent or legal guardian who is competent and willing to provide written informed consent for the active study phase (if under the age of 18);
  • Competent and willing to provide written informed assent for the active study phase (if under the age of 18);
  • Competent and willing to provide written informed consent (if age 18 or older);
  • Able to communicate in English language;
  • Have a parent/guardian who can communicate in English language;
  • Able to commit to 27 study visits in approximately 6 months;
  • Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the investigator.

You may not qualify if:

  • \- Any severe developmental delays (including, but not limited to, Autism Spectrum Disorder, Intellectual Disability, and Down Syndrome).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Adolescent Behavior

Condition Hierarchy (Ancestors)

Behavior

Results Point of Contact

Title
Randi Schuster, PhD
Organization
Massachusetts General Hospital

Study Officials

  • Randi M Schuster, PhD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

December 17, 2018

First Posted

December 24, 2018

Study Start

July 1, 2019

Primary Completion

December 6, 2019

Study Completion

December 6, 2019

Last Updated

August 2, 2024

Results First Posted

August 2, 2024

Record last verified: 2024-02

Locations